C2CD2L

Across TCGA pan-cancer cohorts, C2CD2L Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated C2CD2L data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher C2CD2L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C2CD2L expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

READ, LUSC, and CHOL are the cancer types where C2CD2L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Median	All	0.166	0.830	<.001	20	view →
LUSC	DFS	Median	II,III,IV	0.233	0.711	.002	9	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
LUAD	OS	Median	All	0.276	0.697	.040	3	view →
GBM	DFS	Median	All	1.000	0.248	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

C2CD2L–READ (OS)

Open the READ breakdown →